Entera Bio Ltd.
ENTX
$2.17
-$0.12-5.24%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 181.00K | 99.00K | 57.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 181.00K | 99.00K | 57.00K | -- | -- |
| Cost of Revenue | 172.00K | 90.00K | 48.00K | -- | -- |
| Gross Profit | 9.00K | 9.00K | 9.00K | -- | -- |
| SG&A Expenses | 5.10M | 4.93M | 4.42M | 4.46M | 4.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -10.00K | -22.00K | -36.00K | -49.00K |
| Total Operating Expenses | 9.77M | 9.31M | 8.63M | 8.74M | 8.89M |
| Operating Income | -9.59M | -9.21M | -8.58M | -8.74M | -8.89M |
| Income Before Tax | -9.53M | -9.18M | -8.51M | -8.69M | -8.86M |
| Income Tax Expenses | 14.00K | 0.00 | 29.00K | 29.00K | 29.00K |
| Earnings from Continuing Operations | -9.54 | -9.18 | -8.54 | -8.72 | -8.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.54M | -9.18M | -8.54M | -8.72M | -8.89M |
| EBIT | -9.59M | -9.21M | -8.58M | -8.74M | -8.89M |
| EBITDA | -9.54M | -9.16M | -8.53M | -8.69M | -8.84M |
| EPS Basic | -0.25 | -0.26 | -0.26 | -0.29 | -0.31 |
| Normalized Basic EPS | -0.16 | -0.16 | -0.16 | -0.18 | -0.19 |
| EPS Diluted | -0.25 | -0.26 | -0.26 | -0.29 | -0.31 |
| Normalized Diluted EPS | -0.16 | -0.16 | -0.16 | -0.18 | -0.19 |
| Average Basic Shares Outstanding | 150.58M | 141.07M | 132.23M | 123.96M | 116.03M |
| Average Diluted Shares Outstanding | 150.58M | 141.07M | 132.23M | 123.96M | 116.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |